XML 51 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Other Research and Development Revenue Arrangements (Tables)
12 Months Ended
Dec. 31, 2013
Summary of Total Grant Revenues

Total grant revenues were as follows (in thousands):

 

     Years Ended December 31,  
       2013        2012      2011  

NINDS myasthenia gravis

   $ 69       $ 1,308       $ 1,680   

U.S. Department of the Treasury

     25                   
  

 

 

    

 

 

    

 

 

 

Total grant revenue

   $ 94       $ 1,308       $ 1,680   
  

 

 

    

 

 

    

 

 

Astellas [Member]
 
Summary of Reimbursed Expenses

Research and development revenue from Astellas was as follows (in thousands):

 

     Year Ended
December 31,
2013
 

License revenues

   $ 3,852   

FTE reimbursements

     3,285   

Reimbursements of other costs

     3,130   
  

 

 

 

Total revenue from Astellas

   $ 10,267   
  

 

 

Global Blood [Member]
 
Summary of Reimbursed Expenses

Research and development revenue from Global Blood was as follows (in thousands):

 

     Years Ended December 31,  
       2013        2012      2011  

Expense reimbursements from Global Blood

   $ 14       $ 1,479       $ 266   
  

 

 

    

 

 

    

 

 

MyoKardia [Member]
 
Summary of Reimbursed Expenses

Research and development revenue from MyoKardia was as follows (in thousands):

 

     Years Ended December 31,  
     2013        2012          2011    

Expense reimbursements from MyoKardia

   $ 1,024       $ 595       $